UTHSCSA Faculty Profiles v1.0

Solis-Herrera, Carolina MD

School of Medicine

My major area of interest is in pathophysiology and treatment of type 2 diabetes. This includes mechanisms of action of novel anti-diabetic drugs and its associated molecular and metabolic effects on type 2 diabetes. More recently I have focused my research in diabetes and cardiometabolics. Our group was the first to report multiple of the now known mechanisms of action of the most novel anti-diabetic class of drugs: The SGLT2 inhibitors. This drugs lower plasma glucose levels by increasing glucose excretion thru the urine thru an insulin-independent mechanism. Recently reported cardiovascular outcome trials using this medications have shown a very significant reduction in cardiovascular mortality and hospitalization for heart failure in high risk type 2 diabetic patients, but the mechanism(s) responsible for these cardiovascular benefits remain undefined. My goal is to obtain novel insights in to understanding myocardial metabolism and fuel energetics using state-of the art research techniques including radioisotopes and cardiac imaging to potentially unravel the yet unknown mechanism (s) via which this class of drugs improve heart failure and decrease death from cardiovascular disease. These field is of the highest importance as cardiovascular disease is the number one cause of death in type 2 diabetes patients.

10/2017 - Present Assistant Professor/Clinical University of Texas Health Science Center at San Antonio, Medicine, San Antonio, TX